Zurich, March 02, 2022.  

MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory diseases, announced on the 2nd of March that more than 50% of the number of patients that were planned to be enclosed, have now been enrolled in the Phase II study in COVID-19. The study aims to determine whether the anti-inflammatory effect of MP1032 can slow the spread of the virus in recently hospitalized patients with moderate to severe coronavirus disease and alleviate COVID-19 symptoms. 

MetrioPharm’s Chief Scientific Officer (CSO) Dr. Wolfgang Brysch commented, “Patient enrollment in this international study is progressing steadily. The set schedule has been met so far and we are optimistic to be able to conduct the study as planned. My sincere appreciation goes to the clinical teams on site in the respective hospitals, who are managing this trial in COVID-19 with great, often personal, commitment in the face of high, regular workloads that this pandemic causes.” 

The study aims to recruit 120 patients in an early stage of hospitalization. Approximately 80 patients will receive 300 mg of MP1032 twice a day, plus standard of care, and about 40 patients will receive placebo plus standard of care. The trial is being conducted so far in Romania, Hungary, Spain, Bulgaria and Italy. In addition to confirming the safety of MP1032, the primary efficacy endpoint will be the percentage of participants with improved disease symptoms at Day 14.. First topline data are expected as of Q2 2022. 

About the European Commission funding 

MetrioPharm’s Phase II study in COVID-19 is funded by the European Commission under the HERA Incubator. This program was launched in April 2021 to support urgently needed research and development to combat the corona virus and its variant across Europe. 

MetrioPharm’s iMPact project is part of a broad range of European Commission research and innovation activities to combat the corona virus. 

https://ec.europa.eu 

The iMPact project was nominated for European Commission funding in July 2021, and the grant agreement was signed in November 2021. 

Source: https://www.metriopharm.com/en/news/2022/press-release-march-2022.html